Methods of Administering Elagolix
AssigneeAbbVie Inc.
InventorsMohamad Shebley, Ling Cheng, Pooja Manchandani
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).
Claims12
A method for treating a gynecological disorder in a patient receiving ethinyl estradiol as an oral contraceptive, the method comprising:
- orally administering to the patient elagolix sodium according to an elagolix dosing schedule, and
- discontinuing treatment with ethinyl estradiol prior to initiating administration of elagolix sodium according to the elagolix dosing schedule.
A method for treating a gynecological disorder, the method comprising:
- orally administering to a patient in need thereof elagolix sodium;
- and
- continuing said oral administration for a time period as needed to treat the gynecological disorder;
- wherein the patient uses non-hormonal contraception during treatment with elagolix sodium and for more than 7 days after the time period.
A method for management of moderate to severe pain associated with endometriosis, the method comprising:
- orally administering to a patient in need thereof elagolix sodium, wherein elagolix sodium is administered in an amount equivalent to 150 mg of elagolix free acid once daily, wherein the patient concomitantly receives a combined oral contraceptive, wherein the combined oral contraceptive is administered without an adjustment to a recommended combined oral contraceptive dosing schedule.
A method for management of moderate to severe pain associated with endometriosis, the method comprising:
- orally administering to a patient in need thereof elagolix sodium, wherein elagolix sodium is administered in an amount equivalent to 200 mg of elagolix free acid twice daily;
- wherein the patient receives a dose of 0.1 mg of levonorgestrel;
- and wherein:
- (i) a levonorgestrel Cmax ratio, which compares (A) levonorgestrel Cmax when co-administered in the presence of elagolix to (B) levonorgestrel Cmax when administered alone, is 0.97 with a 90% confidence interval of 0.88-1.07;
- and/or
- (ii) a levonorgestrel AUCinf ratio, which compares (A) levonorgestrel AUCinf when co-administered in the presence of elagolix to (B) levonorgestrel AUCinf when administered alone, is 0.73 with a 90% confidence interval of 0.64-0.82.
Dependencies are inferred from the claim text.